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ABSTRACT 
Venlafaxine is a newly introduced antidepressant that is clinically different from other 
antidepressants, possesses a slightly different mechanism of action and may have unique efficacy 
properties and a faster onset of action. A case of venlafaxine induced severe hypertension is reported 
to highlight the need for caution while using this drug. 
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Venlafaxine is a novel antidepressant that 
is chemically unrelated to tricyclic, tetracyclic and 
other available antidepressants. It is a 
phenylethylamine derivative which produces a 
potent blockade of both 5-HT and nor adrenaline 
uptakes. In this respect the pharmacological 
properties of venlafaxine resemble those of 
cloimipramine. However, unlike cloimipramine, 
venlafaxine has a negligible affinity for other 
neurotransmitter receptor sites and so lacks 
sedative and anticholinergic properties 
(Feighner,1994). It is therefore classified as a 
selective serotonin and nor-adrenaline 
blocker(SNRI). 
Current studies indicate that venlafaxine is 
more effective than placebo and at least of equal 
efficacy to other available antidepressants 
(Silverstone and Ravindran, 1999). Venlafaxine also 
appears to be effective in depressed in patients, 
perhaps more so than fluoxetine(Tzanakaki et 
al.,2000). It is also possible that venlafaxine may 
be of value in treatment resistant cases(Mttchell 
et al.,2000). It has wide dose range from 75-375 
mg/day in two or three divided doses. 
Venlafaxine is generally well tolerated. 
However, the most worrisome side effect is the 
sustained increase in blood pressure in some 
patients, particularly in patients receiving high 
doses. 
CASE REPORT 
A 55 years old lady reported to our OPD 
with features of depression. She was an old case 
of depression since 1975 and has had multiple 
relapses. During her previous episodes she had 
been gives various combinations of antidepressants 
and mood stabilizers with no significant effect. She 
used to improve only after ECT of which she had 
been given several courses in the past. 
In view of the above history, it was decided 
to give her a trial with venlafaxine. She was 
evaluated in detail and was found to have a blood 
pressure of 136/80 mm Hg. There was no past 
history of labile or sustained hypertension. She was 
started on venlafaxine 75mg/day in two divided 
doses which was increased to 150 mg/day in two 
divided doses over the next two weeks. Her blood 
pressure was periodically monitored and she 
remained normotensive. She did not show any 
improvement after three weeks of starting 
venlafaxine and her blood pressure recorded was 
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150/98 mm Hg. She was advised to continue 
venlafaxine 150mg/day. Review after another one 
week revealed no improvement in her mental state 
and her blood pressure was 162/110 mm Hg. 
Venlafaxine was stopped and she was 
advised to get her blood pressure monitored and 
report to the OPD after one week. However, she 
reported to our OPD after a fortnight and was found 
to be normotensive. She had been getting her blood 
pressure checked during that period. It had shown 
a gradual decline within three days of stopping 
venlafaxine. 
She was than given a course of ECT with 
which she improved. She is being regularly reviewed 
and continues to be normotensive. 
and has been maintaining improvement with 
imipramine In fact, lower dose administration over 
a longer period might be a option in those patients 
who develop hypertension at a particular dose. 
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DISCUSSION 
While the majority of clinical studies have 
reported that venlafaxine has not been associated 
with adverse effects on the CVS, a modest increase 
in blood pressure has been reported by several 
studies. An apparently dose related increase in 
systolic blood pressure( by 4 to 11mm Hg after a 
125 to 250 mg dose) was observed after venlafaxine 
administration in 18 healthy volunteers (Fabre & 
Putman, 1987). In patients with depressive illness, 
an increase in diastolic blood pressure of 5.6 mm 
Hg versus baseline occurred following 6 weeks 
treatment with venlafaxine 375mg/day in divided 
doses (Schweizer etal.,1991). Our case developed 
severe hypertension with a relatively modest 
dose of venlafaxine (150 mg/day). She became 
normotensive after a few days of stopping the drug. 
This case highlights the need for regular 
monitoring of blood pressure in patients on 
venlafaxine. The dose of the drug might have to be 
reduced or the drug discontinued in patients who 
experience a sustained increase in blood pressure. 
Re-challenge with the drug was not tried in 
our case as the patient had improved with ECT 
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